Movatterモバイル変換

[0]ホーム
URL:

GB1139869A - Improvements in or relating to tablets - Google Patents

Improvements in or relating to tablets

Info

Publication number
GB1139869A
GB1139869AGB70766AGB70766AGB1139869AGB 1139869 AGB1139869 AGB 1139869AGB 70766 AGB70766 AGB 70766AGB 70766 AGB70766 AGB 70766AGB 1139869 AGB1139869 AGB 1139869A
Authority
GB
United Kingdom
Prior art keywords
water
drug
tablet
tablets
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB70766A
Inventor
David Frederick Cleaver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MOORE MEDICINAL PRODUCTS Ltd
Original Assignee
MOORE MEDICINAL PRODUCTS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MOORE MEDICINAL PRODUCTS LtdfiledCriticalMOORE MEDICINAL PRODUCTS Ltd
Priority to GB70766ApriorityCriticalpatent/GB1139869A/en
Publication of GB1139869ApublicationCriticalpatent/GB1139869A/en
Expiredlegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

1,139,869. Multilayer tablets. MOORE MEDICINAL PRODUCTS Ltd. 6 Jan., 1967 [6 Jan., 1966], No. 707/66. Heading A5B. A multilayer tablet comprises one layer formed from a mixture of a water-soluble drug and a pharmaceutically acceptable waterabsorbent substance which forms one or more stable hydrates (e.g. citric acid or its Na or K salt, or the Na or K salt of tartaric or phosphoric acid), but which is'-present in a fully or partially dehydrated form, the other layer or layers present not being water-absorbent. The other layer, or one of the other layers present may contain a water-insoluble drug. The acids or salts may initially be admixed with the drug in dehydrated form or they may be dehydrated by the action of heat during the preparation of the admixture for the tabletting operation. The example relates to a tablet with a core consisting of sucrose, methylephedrine hydrochloride, theophylline hydrate and magnesium stearate coated with a composition of gelatin, sucrose, talc, isoprenaline sulphate, antioxidants, citric acid and colouring agents. The tablets of the invention ensure that a water-soluble drug is retained in the desired location in the tablet. Enteric coatings may be used where desired.
GB70766A1966-01-061966-01-06Improvements in or relating to tabletsExpiredGB1139869A (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
GB70766AGB1139869A (en)1966-01-061966-01-06Improvements in or relating to tablets

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
GB70766AGB1139869A (en)1966-01-061966-01-06Improvements in or relating to tablets

Publications (1)

Publication NumberPublication Date
GB1139869Atrue GB1139869A (en)1969-01-15

Family

ID=9709143

Family Applications (1)

Application NumberTitlePriority DateFiling Date
GB70766AExpiredGB1139869A (en)1966-01-061966-01-06Improvements in or relating to tablets

Country Status (1)

CountryLink
GB (1)GB1139869A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP0013131A3 (en)*1978-12-271981-01-07Mundipharma A.G.Pharmaceutical composition in solid dosage form, and process for its production
FR2470599A1 (en)*1979-12-071981-06-12Panoz Donald IMPROVEMENTS IN PROCESSES FOR THE PREPARATION OF GALENIC SHAPES WITH DELAYED ACTION AND PROGRAMMED RELEASE AND GALENIC FORMS OF MEDICAMENTS THUS OBTAINED
EP0111144A1 (en)*1982-11-011984-06-20Merrell Dow Pharmaceuticals Inc.Sustained release solid dosage forms having non-uniform distribution of active ingredient
WO2004050067A1 (en)*2002-11-292004-06-17Cipla LimitedPHARMACEUTICAL FORMULATIONS COMPRISING β-2 ADRENORECEPTOR AGONISTS AND XANTHINES

Cited By (8)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP0013131A3 (en)*1978-12-271981-01-07Mundipharma A.G.Pharmaceutical composition in solid dosage form, and process for its production
FR2470599A1 (en)*1979-12-071981-06-12Panoz Donald IMPROVEMENTS IN PROCESSES FOR THE PREPARATION OF GALENIC SHAPES WITH DELAYED ACTION AND PROGRAMMED RELEASE AND GALENIC FORMS OF MEDICAMENTS THUS OBTAINED
WO1981001652A1 (en)*1979-12-071981-06-25D PanozImprovements to methods for preparing galenical preparation with delayed action and programmed release and galenical preparations for drugs obtained thereby
US5051262A (en)*1979-12-071991-09-24Elan Corp., P.L.C.Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained thereby
EP0111144A1 (en)*1982-11-011984-06-20Merrell Dow Pharmaceuticals Inc.Sustained release solid dosage forms having non-uniform distribution of active ingredient
WO2004050067A1 (en)*2002-11-292004-06-17Cipla LimitedPHARMACEUTICAL FORMULATIONS COMPRISING β-2 ADRENORECEPTOR AGONISTS AND XANTHINES
GB2410187A (en)*2002-11-292005-07-27Cipla LtdPharmaceutical formulations comprising ß-2 adrenoreceptor agonists and xanthines
GB2410187B (en)*2002-11-292007-06-20Cipla LtdPharmaceutical formulations comprising ß-2 adrenoreceptor agonists and xanthines

Similar Documents

PublicationPublication DateTitle
GB1517480A (en)Opiate analgesic formulation with a low potential for abuse
ATE15599T1 (en) DELAYED RELEASE PHARMACEUTICAL PREPARATION.
IL47656A0 (en)Sulphonic acid salts of s-adenosilmethionine,their preparation and pharmaceutical compositions containing them
GB1359614A (en)Method for the manufacture of effervescent tablets
GB1059508A (en)Coating tablets
ES8200657A1 (en)Stable composition of S-adenosyl-L-methionine
GB1296505A (en)
IE36335L (en)Sustained/immediate release veterinary layered bolus
GB1139869A (en)Improvements in or relating to tablets
EP0013131A2 (en)Pharmaceutical composition in solid dosage form, and process for its production
CA983030A (en)2-(substituted pyrrolidino)-8-lower alkyl-5,8-dihydro-5-oxopyrido(2,3-d) pyrimidine-6-carboxylic acid derivatives, and process for the preparation of the same
US2373763A (en)Enteric coating
US3696188A (en)Laminated tablets
GB1422193A (en)Pharmaceutical compositions
US3066075A (en)Compositions comprising amphetamine and carboxymethyl cellulose in chemically combined form
US3297530A (en)Antidepressant compositions and methods of using same
GB1233055A (en)
US2714084A (en)Enteric coated tablets and methods of making the same
US3279997A (en)Enteric coated calcium lactate tablets containing an antihistamine and thiamine chloride
US2099403A (en)Split action tablet
AU461018B2 (en)Process for producing 4-hydroxymethyl-1-keto-1 2-dihydrophthalazine and acid salts thereof and pharmaceutical composition containing thesame
IE34386L (en)Acetylsalicylic acid-containing composition
GB953102A (en)Therapeutic compositions useful for inducing sleep
IL38701A0 (en)Substituted pyrazol(3)yl-carbamic acid esters,their preparation,and their use as insecticides or acaricides
GB1338541A (en)Therapeutic compositions containing sulphamethyoxypyridazine or sulphaethoxypyridazine
[8]ページ先頭
©2009-2025 Movatter.jp